These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 18361950

  • 1. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
    Alder J.
    Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ.
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [Abstract] [Full Text] [Related]

  • 3. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.
    French GL.
    J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922
    [Abstract] [Full Text] [Related]

  • 4. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care.
    Tverdek FP, Crank CW, Segreti J.
    Crit Care Clin; 2008 Apr; 24(2):249-60, vii-viii. PubMed ID: 18361944
    [Abstract] [Full Text] [Related]

  • 5. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
    Vikram HR, Havill NL, Koeth LM, Boyce JM.
    J Clin Microbiol; 2005 Oct; 43(10):5384-7. PubMed ID: 16208025
    [Abstract] [Full Text] [Related]

  • 6. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
    Mohan SS, McDermott BP, Cunha BA.
    Heart Lung; 2005 Oct; 34(1):69-71. PubMed ID: 15647736
    [Abstract] [Full Text] [Related]

  • 7. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.
    Skiest DJ.
    J Clin Microbiol; 2006 Feb; 44(2):655-6. PubMed ID: 16455939
    [Abstract] [Full Text] [Related]

  • 8. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis.
    Rouse MS, Piper KE, Jacobson M, Jacofsky DJ, Steckelberg JM, Patel R.
    J Antimicrob Chemother; 2006 Feb; 57(2):301-5. PubMed ID: 16361330
    [Abstract] [Full Text] [Related]

  • 9. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR.
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [Abstract] [Full Text] [Related]

  • 10. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
    Carpenter CF, Chambers HF.
    Clin Infect Dis; 2004 Apr 01; 38(7):994-1000. PubMed ID: 15034832
    [Abstract] [Full Text] [Related]

  • 11. Daptomycin, a lipopeptide antibiotic in clinical practice.
    Weis F, Beiras-Fernandez A, Schelling G.
    Curr Opin Investig Drugs; 2008 Aug 01; 9(8):879-84. PubMed ID: 18666036
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry.
    Martone WJ, Lamp KC.
    Curr Med Res Opin; 2006 Dec 01; 22(12):2337-43. PubMed ID: 17257448
    [Abstract] [Full Text] [Related]

  • 13. Treatment of staphylococcal infections with cyclic lipopeptides.
    Eisenstein BI.
    Clin Microbiol Infect; 2008 Mar 01; 14 Suppl 2():10-6. PubMed ID: 18226085
    [Abstract] [Full Text] [Related]

  • 14. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.
    Boucher HW, Sakoulas G.
    Clin Infect Dis; 2007 Sep 01; 45(5):601-8. PubMed ID: 17682996
    [Abstract] [Full Text] [Related]

  • 15. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN, Alder J, Thorne GM, Tally FP.
    J Antimicrob Chemother; 2005 Mar 01; 55(3):283-8. PubMed ID: 15705644
    [Abstract] [Full Text] [Related]

  • 16. Pre-clinical experience with daptomycin.
    Hawkey PM.
    J Antimicrob Chemother; 2008 Nov 01; 62 Suppl 3():iii7-14. PubMed ID: 18829726
    [Abstract] [Full Text] [Related]

  • 17. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW, Murray CK, Holmes RL, Patterson JE, Jorgensen JH.
    Diagn Microbiol Infect Dis; 2008 Apr 01; 60(4):437-40. PubMed ID: 18096352
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
    Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP.
    J Antimicrob Chemother; 2003 Sep 01; 52(3):405-11. PubMed ID: 12917254
    [Abstract] [Full Text] [Related]

  • 19. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
    Kanafani ZA, Corey GR.
    Expert Rev Anti Infect Ther; 2007 Apr 01; 5(2):177-84. PubMed ID: 17402833
    [Abstract] [Full Text] [Related]

  • 20. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI, Mejías A, Katz KS, Revell P, McCracken GH, Sánchez PJ.
    Pediatr Infect Dis J; 2007 Dec 01; 26(12):1128-32. PubMed ID: 18043450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.